Needle Stick Protocol: What to Do Immediately, Reporting, Testing, and Post-Exposure Prophylaxis (PEP)

Immediate Care of Exposure Site

Act within minutes. Early percutaneous exposure management reduces risk and speeds access to care. Stop the task, remove contaminated gloves or PPE, and move to a sink or eyewash station.

• Skin (percutaneous or cut): Wash thoroughly with soap and running water. Allow gentle bleeding but do not squeeze, cut, or use caustic agents (bleach, iodine, hydrogen peroxide).
• Mucous membranes (mouth, nose): Rinse copiously with water or normal saline for several minutes; do not swallow rinse water.
• Eyes: Irrigate at an eyewash station with saline or clean water for at least 15 minutes; remove contact lenses during flushing.

Secure the device if safe (e.g., safety-engage, place in a sharps container) and note details about the source material and exposure mechanism. Do not delay reporting or PEP evaluation to continue patient care.

Reporting the Incident

Immediately notify your supervisor and Occupational Health or the designated exposure hotline. If after hours, use the facility’s 24/7 pathway (e.g., Emergency Department) for occupational exposure reporting and initial evaluation.

Provide the source patient’s identifiers if known, the device or instrument type, and any available lab information. Maintain confidentiality for both you and the source patient, and follow institutional and state requirements for Occupational Exposure Reporting.

Completing an Incident Report

Finish incident documentation as soon as feasible the same shift. Accurate, prompt records support care decisions, regulatory compliance, and quality improvement.

• Date/time, location, and task being performed.
• Exposure type (percutaneous, mucous membrane, nonintact skin) and depth/severity.
• Device or instrument (needle gauge/safety feature) and whether blood or potentially infectious material was visible.
• PPE worn at the time and immediate first aid performed.
• Source patient details if available (diagnoses, known HIV/HBV/HCV status, recent high-risk factors).
• Witnesses and control measures to prevent recurrence.

Attach or upload any required forms, photos of device packaging if relevant, and the initial clinical assessment to complete the record.

Initiating Post-Exposure Prophylaxis

Risk assessment and timing

Begin evaluation immediately. Use your facility’s Post-Exposure Prophylaxis Guidelines to assess transmission risk based on fluid type, exposure depth, and source status. Start HIV PEP as soon as possible—ideally within hours—and generally not later than 72 hours after exposure.

HIV PEP (antiretroviral regimen)

• Typical approach: a three-drug, integrase inhibitor–based HIV antiretroviral regimen for 28 days, unless contraindicated.
• Baseline labs: HIV Ag/Ab test, renal and hepatic function, pregnancy test when relevant, and other tests per protocol.
• First follow-up: clinical review within 3–7 days to assess adherence, side effects, and any lab results that may allow regimen adjustment or discontinuation.

If rapid source testing is negative for HIV and no window-period concern exists, PEP may be discontinued per protocol. Always apply local policies and individual clinical judgment.

Hepatitis B exposure management

• Check your vaccination history and anti-HBs titer if available.
• If nonimmune or status unknown, begin HBV vaccination promptly; administer HBIG as soon as possible (ideally within 24 hours; effectiveness diminishes beyond 7 days for percutaneous exposures).
• If previously vaccinated with documented anti-HBs ≥10 mIU/mL, no HBV PEP is typically needed.

Hepatitis C exposure management

• No proven PEP exists. Do not start antivirals prophylactically.
• Obtain baseline HCV testing and arrange early HCV RNA testing; prompt referral if viremia is detected.

Other considerations

• Drug–drug interactions, renal/hepatic comorbidities, pregnancy, and lactation require tailored choices—consult infectious diseases or Occupational Health.
• Document all decisions and patient counseling in the medical record to align with incident documentation standards.

Counseling and Follow-Up

Provide clear counseling on risk, PEP adherence, and safety while results are pending. Emphasize that early, consistent medication use and timely follow-up serology are critical for effective percutaneous exposure management.

• Safety practices during follow-up: use barrier protection, avoid blood or tissue donation, do not share razors or toothbrushes, and seek guidance regarding breastfeeding or attempting conception.
• Monitoring: check for side effects within the first week and as needed thereafter; repeat renal/hepatic labs per regimen.

Suggested follow-up testing schedule (adjust per protocol)

• HIV: baseline, then at approximately 6 weeks and 12 weeks after exposure using a 4th-generation Ag/Ab test; extend to 6 months if using older assays or if special circumstances apply.
• HBV: baseline HBsAg/anti-HBs; if vaccinated or given HBIG, perform follow-up serology per policy (e.g., anti-HBs 1–2 months after the final vaccine dose; defer anti-HBs ≥6 months after HBIG to avoid interference).
• HCV: baseline; HCV RNA at 3–6 weeks, then anti-HCV at 4–6 months (or per local algorithm).

Schedule all visits before leaving the initial encounter, and provide a direct contact for questions or worsening symptoms.

Wound Care

Keep the site clean, dry, and uncovered unless drainage requires a breathable dressing. Avoid squeezing, scrubbing, or topical caustics that can worsen tissue injury.

• Change dressings if soiled and monitor for redness, swelling, warmth, or discharge.
• Review tetanus immunization; provide Tdap booster per routine wound management guidance if indicated.
• Do not suture puncture wounds solely to close the entry site; allow natural drainage unless otherwise clinically indicated.

Source Patient Testing

Obtain informed consent according to jurisdictional law and facility policy. Use Source Patient Serologic Testing to inform risk rapidly, but never delay starting indicated PEP while awaiting results.

• HIV: rapid 4th-generation Ag/Ab test when available; consider RNA testing if acute HIV is suspected.
• HBV: HBsAg to determine infectiousness; add other markers per protocol.
• HCV: anti-HCV with reflex HCV RNA if positive; in high-risk, consider direct HCV RNA testing.

Protect confidentiality. Communicate results to appropriate care teams only, document in the exposure record, and update your management plan immediately if results change risk assessment.

Conclusion

Act fast, report immediately, document completely, start appropriate PEP without delay, and complete follow-up serology. Align each step with your facility’s Post-Exposure Prophylaxis Guidelines to protect your health and ensure safe, consistent care.

FAQs.

What immediate steps should be taken after a needle stick injury?

Stop work, remove contaminated PPE, and perform first aid: wash skin with soap and water, flush mucous membranes with water or saline, and irrigate eyes at an eyewash station. Secure the device safely, note exposure details, and report the incident at once for risk assessment and timely PEP.

How soon must post-exposure prophylaxis be started?

Initiate HIV PEP as soon as possible—ideally within hours of the exposure—and generally not later than 72 hours. Do not wait for source testing to start indicated PEP; treatment can be adjusted or stopped if results later show no risk.

When should follow-up testing be performed?

Obtain baseline labs immediately. Common schedules include HIV testing at about 6 and 12 weeks after exposure (extend to 6 months in select cases), HCV RNA at 3–6 weeks with anti-HCV at 4–6 months, and HBV follow-up serology per vaccination/HBIG status.

How is the source patient tested and informed?

With informed consent and according to local law, perform rapid HIV Ag/Ab testing, HBsAg for HBV, and anti-HCV with reflex RNA (or direct RNA if high suspicion). Results are communicated confidentially through designated clinical channels; they guide your management but do not replace prompt initiation of indicated PEP.